*This information is for general informational purposes only, we will not be liable for any loss or damage caused by the above information. ![]() With a focus on energy efficiency and sustainability, ADI is a leader in the analog and mixed-signal IC industry, driving technological advancements and providing innovative solutions to the world's most challenging problems. The company's product portfolio includes data converters, amplifiers and comparators, power management ICs, microcontrollers, sensors, and radio frequency (RF) and microwave components, among others.ĪDI is dedicated to innovation and customer satisfaction, and is committed to providing its customers with high-quality, reliable solutions to meet their needs. ARQ 092 is an orally available, selective pan-AKT inhibitor. An oral presentation of preclinical studies with ARQ 092 in Sickle Cell Disease will be presented by ArQule’s collaborator, the University of Illinois College of Medicine. The company was founded in 1965 and is headquartered in Norwood, Massachusetts.ĪDI serves a wide range of industries, including aerospace and defense, automotive, communications, consumer, industrial, medical, and test and measurement. ARQ 531 is an investigational, orally bioavailable, potent and reversible Brutons tyrosine kinase (BTK) inhibitor. (ADI) is a publicly traded company that designs, develops, and manufactures high-performance analog, mixed-signal, and digital signal processing (DSP) integrated circuits (ICs). Microphone Preamplifier with Variable Compression and Noise GatingĪnalog Devices, Inc. Ultralow Noise VGAs with Preamplifier and Programmable Rĭual VGA with Ultralow Noise Preamplifier and Programmable RINĬascadable IF VGAs with Programmable RMS Detectors Ultralow Noise VGAs with Preamplifier and Programmable RIN Low output-referred noise: 48 nV/√Hz typicalĪD8332 and AD8334 available in lead frame chip scale package Wide gain range with programmable postamp ARQ 531 is not metabolized by any of the major drug metabolizing CYP450 enzymes. BTK is a key regulator of the B cell receptor (BCR) signaling pathway that mediates signaling from the cell surface to the cytoplasm and into the nucleus. Using a single resistor, the LNA input impedance can be adjusted to match a signal source without compromising noise performance. Background: ARQ 531 is a novel, ATP competitive reversible inhibitor Brutons tyrosine kinase (BTK). The LNA gain is 19 dB with a single-ended input and differential outputs. Included in each channel are an ultralow noise preamplifier (LNA), an X-AMP® VGA with 48 dB of gain range, and a selectable gain postamplifier with adjustable output limiting. Optimized for ultrasound systems, they are usable as a low noise variable gain element at frequencies up to 120 MHz. The AD8331/AD8332/AD8334 are single-, dual-, and quad channel ultralow noise, linear-in-dB, variable gain amplifiers (VGAs).
0 Comments
Leave a Reply. |